Axe Compute (NASDAQ:AGPU) Upgraded to “Buy” at Wall Street Zen

Axe Compute (NASDAQ:AGPU – Get Free Report) was upgraded by stock analysts at Wall Street Zen from a “hold” rating to a “buy” rating in a report issued on Saturday, Wall Street Zen reports.

A number of other analysts also recently weighed in on the stock. Weiss Ratings reiterated a “sell (d-)” rating on shares of Axe Compute in a research report on Thursday, August 27th. JonesTrading raised shares of Axe Compute to a “strong-buy” rating in a research note on Saturday, September 26th. One equities research analyst has rated the stock with a Strong Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy”.

Get Our Latest Report on Axe Compute

Axe Compute Stock Performance

Axe Compute stock opened at $5.67 on Friday. Axe Compute has a 1 year low of $1.03 and a 1 year high of $13.49. The business has a 50-day moving average of $9.49 and a 200-day moving average of $6.80.

Institutional Investors Weigh In On Axe Compute

A hedge fund recently bought a new stake in Axe Compute stock. Vise Technologies Inc. purchased a new position in shares of Axe Compute Inc (NASDAQ:AGPU – Free Report) during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm purchased 53,848 shares of the company’s stock, valued at approximately $612,000. Vise Technologies Inc. owned 0.46% of Axe Compute at the end of the most recent reporting period. 9.04% of the stock is currently owned by hedge funds and other institutional investors.

About Axe Compute

(Get Free Report)

Predictive Oncology Inc., a knowledge-driven company, focuses on developing personalized cancer therapies using artificial intelligence (AI) primarily in the United States. The company operates in four segments: Helomics, zPREDICTA, Soluble, and Skyline. The Helomics segment offers clinical testing services comprising tumor drug response testing and genomic profiling tests; and contract research services through patient-centric drug discovery using active learning technology for discovery, clinical and translational research, clinical trials, and diagnostic development and validation.

Further Reading

Receive News & Ratings for Axe Compute Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Axe Compute and related companies with MarketBeat.com's FREE daily email newsletter.